Funding (ICMUB): 125 600 €
Duration: Jan. 2022 – 48 months
Scientific leader ICMUB: DENAT Franck
Description :
The brain is by far our most precious organ. This is why it is protected by the blood-brain barrier (BBB), which restricts the passage of pathogens and toxins that may be present in our blood. However, this restriction becomes a limitation in the treatment of brain diseases, such as gliomas. The therapeutic resistance of gliomas can be explained by insufficient drug accumulation in tumor cells and poor therapeutic choices. We propose to define a new therapeutic strategy by redirecting targeted internal radiotherapy towards gliomas. This involves studying complementary strategies to overcome the BBB’s limitation: (i) identifying and targeting highly specific glioma biomarkers, such as endothelin receptors, (ii) developing optimized antibody-based ligands against these biomarkers, and (iii) evaluating focused ultrasound delivery strategies to enhance local drug concentration. This project aims to improve survival outcomes for glioma patients.
Total: 504 600 €
Partners:
- – CEA équipe BioMaps (coordinateur Charles TROUILLET)
- – CEA (LENIT)
- – Université de Montpellier/ Institut de Génomique Fonctionnelle